π•„π• π••π•–π•£π•Ÿπ•’ 𝕑𝕦𝕝𝕝𝕀 π•’π•‘π•‘π•π•šπ•”π•’π•₯π•šπ• π•Ÿ 𝕗𝕠𝕣 π•Ÿπ•–π•¨ ℂ𝕆𝕍𝕀𝔻-𝕗𝕝𝕦 π•”π• π•žπ•“π•šπ•Ÿπ•’π•₯π•šπ• π•Ÿ 𝕀𝕙𝕠π•₯ π• π•—π•—π•π•šπ•Ÿπ•–

Moderna (MRNA.O) said on Wednesday it has withdrawn an application seeking approval for its flu and COVID combination vaccine candidate to wait for efficacy data from a late-stage trial of its influenza shot, which is due later this year.

The delay was largely expected after Moderna said earlier this month that it does not anticipate approval of the shot until 2026 due to the need for more data on the flu vaccine.

ℝ𝕖𝕦π•₯𝕖𝕣𝕀

𝕋𝕙𝕖 β„‚π• π•Ÿπ•€π•–π•£π•§π•’π•₯π•šπ•§π•– 𝔸𝕝π•₯π•–π•£π•Ÿπ•’π•₯π•šπ•§π•–

Source